Editas Medicine's Restricted Cash Holds Steady at $3,877

Ticker: EDIT · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1650664

Sentiment: neutral

Topics: Biotechnology, Gene Editing, 10-Q Filing, Restricted Cash, Financial Stability, Asset Management, Corporate Finance

Related Tickers: EDIT

TL;DR

Editas Medicine's restricted cash is flat, signaling a holding pattern for the gene-editing firm.

AI Summary

Editas Medicine, Inc. reported restricted cash of $3,877 as of June 30, 2025, which remained unchanged from June 30, 2024. The filing indicates no significant changes in the company's financial position regarding restricted cash over the past year. The company's common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings balances were tracked from December 31, 2024, through June 30, 2025, and for the comparable periods in 2024. While specific revenue and net income figures are not detailed in the provided excerpt, the consistent restricted cash balance suggests a stable, albeit potentially stagnant, liquidity position in this specific category. The strategic outlook and key business changes cannot be fully assessed without more comprehensive financial statements, but the consistent restricted cash figure implies no immediate major shifts in long-term asset allocation or significant new restrictions on cash. Risks related to operational funding or market conditions are not discernible from this limited data.

Why It Matters

For investors, the unchanging restricted cash balance of $3,877 from June 30, 2024, to June 30, 2025, suggests a lack of significant new long-term commitments or releases of restricted funds, which could indicate a stable but not rapidly expanding operational footprint. This stability might be viewed positively for risk-averse investors seeking predictability in a volatile biotech sector, but it also signals a lack of new major partnerships or regulatory milestones that would typically impact such balances. Employees and customers are unlikely to be directly impacted by this specific metric, but the broader market might interpret this as Editas maintaining its current strategic course without major new initiatives that would require substantial restricted capital. In a competitive landscape, this could mean Editas is not aggressively pursuing large-scale projects that demand significant upfront restricted capital, potentially lagging competitors who are.

Risk Assessment

Risk Level: medium — The risk level is medium because while the restricted cash balance of $3,877 is stable, the absence of detailed revenue, net income, or operational cash flow data prevents a full assessment of the company's financial health and burn rate. A stable restricted cash balance alone does not guarantee overall financial stability or mitigate risks associated with clinical trial failures or competitive pressures in the biotech industry.

Analyst Insight

Investors should seek further details on Editas Medicine's overall cash position, revenue streams, and R&D pipeline progress beyond this restricted cash figure. This limited data suggests a 'wait and see' approach, as the stability of restricted cash doesn't provide enough information to make a definitive investment decision without understanding broader financial performance and strategic developments.

Key Numbers

Key Players & Entities

FAQ

What was Editas Medicine's restricted cash balance as of June 30, 2025?

Editas Medicine, Inc. reported a restricted cash balance of $3,877 as of June 30, 2025, which was consistent with the balance reported on June 30, 2024.

How did Editas Medicine's restricted cash change year-over-year?

Editas Medicine's restricted cash remained unchanged at $3,877 from June 30, 2024, to June 30, 2025, indicating no movement in this specific asset category.

What does the stable restricted cash balance imply for Editas Medicine?

A stable restricted cash balance of $3,877 suggests that Editas Medicine has not initiated new projects requiring significant restricted funds nor released existing restrictions on cash during the period from June 30, 2024, to June 30, 2025.

Where is restricted cash reported on Editas Medicine's balance sheet?

Restricted cash of $3,877 is included in 'Restricted cash and other non-current assets' on Editas Medicine's Consolidated Balance Sheet.

What is the significance of restricted cash for Editas Medicine investors?

For Editas Medicine investors, the consistent restricted cash balance of $3,877 indicates stability in long-term asset commitments but provides limited insight into overall operational performance or strategic growth without additional financial data.

Did Editas Medicine's common stock change during Q2 2025?

The provided data tracks common stock balances for Editas Medicine from December 31, 2024, through June 30, 2025, but does not specify the exact change in value during Q2 2025 without further detail.

What is the fiscal year end for Editas Medicine, Inc.?

The fiscal year end for Editas Medicine, Inc. is December 31, as stated in the filing data.

What is Editas Medicine's primary business classification?

Editas Medicine, Inc.'s Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]', indicating its focus on biological product development.

When was Editas Medicine's 10-Q for Q2 2025 filed?

Editas Medicine's 10-Q filing for the period ended June 30, 2025, was filed on August 12, 2025.

What is the central index key (CIK) for Editas Medicine?

The Central Index Key (CIK) for Editas Medicine, Inc. is 0001650664.

Industry Context

Editas Medicine operates in the biotechnology sector, specifically focusing on gene editing technologies. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial funding to advance their pipelines, making cash position and access to capital critical.

Regulatory Implications

As a gene editing company, Editas Medicine is subject to stringent regulatory oversight from bodies like the FDA. Any delays or setbacks in clinical trials or regulatory approvals can significantly impact the company's financial outlook and operational progress. Compliance with evolving gene editing regulations is paramount.

What Investors Should Do

  1. Monitor R&D Spend and Pipeline Progress
  2. Analyze Cash Burn Rate

Key Dates

Glossary

Restricted cash
Cash that a company is legally or contractually obligated not to spend. This can include funds held in escrow or pledged as collateral. (The filing notes restricted cash of $3,877 as of June 30, 2025, which remained unchanged from the prior year, indicating no new significant restrictions or allocations of cash.)
Additional Paid-In Capital
The amount of capital raised by a company from the issuance of stock above its par value. (This is a key component of shareholders' equity, reflecting capital contributed by investors beyond the nominal value of the stock.)
Accumulated Other Comprehensive Income
A component of shareholders' equity that includes unrealized gains and losses on certain investments, foreign currency translation adjustments, and pension plan adjustments. (Changes in this account can indicate fluctuations in the value of certain assets or liabilities not reflected in net income.)
Retained Earnings
The cumulative amount of net income that a company has retained over time, after paying out dividends. (This reflects the company's historical profitability and its policy on reinvesting earnings back into the business.)

Year-Over-Year Comparison

The provided excerpt focuses on restricted cash, which remained unchanged at $3,877 between June 30, 2024, and June 30, 2025. This indicates a stable, albeit very small, component of the company's assets. Without broader financial statements, a comprehensive comparison of revenue growth, margin changes, or the emergence of new risks compared to the previous filing is not possible from this limited data.

Filing Stats: 4,624 words · 18 min read · ~15 pages · Grade level 17.3 · Accepted 2025-08-12 16:08:44

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 35

OTHER INFORMATION

PART II. OTHER INFORMATION 36 Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 5. Other Information 38 Item 6. Exhibits 39

Signatures

Signatures 40 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Editas Medicine, Inc. Condensed Consolidated Balance Sheets (unaudited) (amounts in thousands, except share and per share data) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 138,542 $ 131,541 Marketable securities 39,959 138,372 Accounts receivable 588 16,266 Prepaid expenses and other current assets 3,707 3,136 Total current assets 182,796 289,315 Property and equipment, net 4,576 14,497 Right-of-use assets 19,011 32,554 Restricted cash and other non-current assets 4,198 5,223 Total assets $ 210,581 $ 341,589 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 6,723 $ 5,493 Accrued expenses 48,068 45,859 Liability for sale of future revenues, current 5,000 5,000 Deferred revenue, current — 6,221 Operating lease liabilities 6,146 14,652 Total current liabilities 65,937 77,225 Operating lease liabilities, net of current portion 14,989 20,380 Liability for sale of future revenues - non-current 51,670 52,434 Deferred revenue, net of current portion 54,204 54,204 Other non-current liabilities 4,592 3,072 Total liabilities 191,392 207,315 Stockholders' equity Preferred stock, $ 0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding — — Common stock, $ 0.0001 par value per share: 390,000,000 and 195,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 87,388,425 and 82,734,696 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 9 8 Additional paid-in capital 1,616,931 1,602,441 Accumulated other comprehensive income 15 268 Accumulated deficit ( 1,597,766 ) ( 1,468,443 ) Total stockholders' equity 19,189 134,274 Total liabilities and stockholders' equity $ 210,581 $ 341,589 The accompanying notes are an integral part of the condensed consolidated financial statements. 3 Table of Contents Editas Medicine, Inc. Condensed Consolidated Statements

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing